Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? - Wikidata - awgldk - TriplyDB

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

http://www.wikidata.org/entity/Q34101898

about

Optimizing treatment success in multiple sclerosis Progressive multiple sclerosis The effects of pregabalin and the glial attenuator minocycline on the response to intradermal capsaicin in patients with unilateral sciatica Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis Clinical relevance of brain volume measures in multiple sclerosis.A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms.Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.The magnetic resonance imaging 'rule of five': predicting the occurrence of relapse.Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.Ibudilast (AV411), and its AV1013 analog, reduce HIV-1 replication and neuronal death induced by HIV-1 and morphine Disability, atrophy and cortical reorganization following spinal cord injury.Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives Multiple sclerosis review.The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.Modelling and sample size reestimation for longitudinal count data with incomplete follow up.Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine.Inhibition of phosphodiesterase-4 promotes oligodendrocyte precursor cell differentiation and enhances CNS remyelination.Translational research in neurology and neuroscience 2010: multiple sclerosis Approaches to neuroprotective strategies in multiple sclerosis.MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.Advances in imaging to support the development of novel therapies for multiple sclerosis.Drugs in development for relapsing multiple sclerosis.Neuroprotection in multiple sclerosis: a therapeutic approach.Novel therapeutic options for multiple sclerosis.Modulating the delicate glial-neuronal interactions in neuropathic pain: promises and potential caveats.Chronic Daily Headache: Mechanisms and Principles of Management.The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.Endogenous repair and development inspired therapy of neurodegeneration in progressive multiple sclerosis.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Tracking the Evolution of Cerebral Gadolinium-Enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline.Ibudilast for the treatment of multiple sclerosis.Glial Attenuation With Ibudilast in the Treatment of Medication Overuse Headache: A Double-Blind, Randomized, Placebo-Controlled Pilot Trial of Efficacy and Safety.Therapeutic Strategies Under Development Targeting Inflammatory Mechanisms in Amyotrophic Lateral Sclerosis.Immune Modulation in the Treatment of Amyotrophic Lateral Sclerosis: A Review of Clinical Trials.Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study.

P2860

Q26771968-0126E868-DBCB-4148-AAAB-5EEDDB2A23AE Q26861772-DCC50AFB-A124-40B8-8CE4-45347F3D18A9 Q28484151-4DC90070-61BD-4101-99A7-9FF1B1D40F7F Q28545984-E3C06ED6-8D4E-46A3-B203-972C83CC3E3F Q30276131-47B20EC6-2323-4401-8230-92E6DC4AE8D3 Q30738659-DF2D339A-E89A-4BC3-A16F-22BDCFF8A51C Q30844551-09CD1F9A-1FB9-427A-A86E-C409662CA970 Q33873538-BDB71246-5CEE-4781-A251-21D7CD7055D5 Q33988240-41C9043D-34A2-430E-9798-63D2BCB43C94 Q34003724-B2ABCA5C-520E-4913-A5C6-3B188FE3F5BA Q34026205-B3DEFD88-6C0D-499C-8A3F-471ACD84E29B Q34311105-49FE201B-A43D-4334-B030-BB8CB7895D19 Q34988973-B0E24B46-764F-41F0-9781-C812F2D38475 Q35007867-14CB780A-761A-424C-BFCB-706204E5D478 Q35182733-704AEE4E-76FF-48C5-880B-FC21CE446005 Q35958691-E798755B-7691-4AAC-B3D9-EE513CAABF99 Q36279074-0D7659E1-58D6-4A11-98B4-EC31ED6F4A49 Q36353053-A6D5DE40-973E-4FA6-8656-C453EB511C01 Q36410659-348AF0B2-05FF-409F-8EB0-27A08F3B85D0 Q36484443-9E08DCB7-6328-42DE-B4E5-FBE6293E34ED Q37395650-51CF9E95-B8A0-4DD6-9057-6FFD83E22C90 Q37557188-DC2ABB82-5579-49E9-8198-AE89A99F2E01 Q37772026-0D359C4D-12D0-47EB-AA9D-4854C6FC1E13 Q37778062-AF74E7F2-FCCD-4F51-85F2-39F4AEAF662D Q37964985-D61F6715-FE08-46DF-9F5D-FB06F9F1A5E1 Q37991519-C0349A2D-F510-4E91-95FD-5422AFB0CDF7 Q38101004-CAC0E6E4-AF49-4496-967A-440D6F8E79E1 Q38129748-093A4F7A-A5A6-4E41-B21D-0E598B26F910 Q38170129-EDCAE86E-28BD-4DD1-A06E-3AFF76548B9D Q38211273-B5F7FAAE-0967-4152-A5CC-344D0F1262ED Q38700966-0A935B24-D49C-49B5-92A7-CD0502B1824F Q38761495-00B9721B-D7AE-4DF4-8B83-DE19E0965011 Q38765008-41AFB40F-4CDE-4515-AE00-BEDA9C9727BE Q38837294-519CA563-69B3-4436-8286-7F0DE75EFF78 Q38859250-26B7ED64-A503-40D3-8908-B2A4892DFB2C Q38921778-232E5DA1-38CD-4C43-99BA-A22E57E43F55 Q38964185-5A5ABE1D-0D3F-4183-94A7-EAF22B8C6BCD Q39271545-16DE5387-CA00-4313-BDF7-25EE984A96BC Q42367893-373C085C-CB3B-48F1-A3A8-E52737417A2C Q44887683-5CE4D76B-D857-42D2-B727-6687CD7ABEC2

P2860

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

http://www.wikidata.org/entity/Q34101898

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@ast

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@en

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@nl

type

label

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@ast

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@en

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@nl

prefLabel

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@ast

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@en

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@nl

P1433

Q34101898-A3A14DA3-D8CF-4D81-A930-3589ECAF3824

P1476

Q34101898-E858B3E9-C8F5-4128-9431-34D44E6575DB

P2093

Q34101898-04436E3C-22E7-4E36-AA33-B257E9440BAA

Q34101898-1246F6AF-620D-46CC-B2E3-E3A4A33F4585

Q34101898-16C12AD2-5416-43E7-8077-D725114E3995

Q34101898-5A046D74-57EB-49B2-9935-0E93EDC98571

Q34101898-656A3A45-5643-4DE4-AE7D-B1C98B2F96D6

Q34101898-98B058F4-EF98-4496-B737-6CE9F0CC401E

Q34101898-F6797C19-9674-4E5B-8CDC-AC26C95B4DCD

P304

Q34101898-A5647AEA-E9A6-472F-BA12-E52425E8B1A4

P31

Q34101898-7D928350-E196-4E4E-899B-426A1E02F9D4

P356

Q34101898-79823A61-FB42-4A84-BB6F-F41E75FF9EA2

P407

Q34101898-EF0B21FE-AB6B-4934-BA81-7695B8D9CF09

P433

Q34101898-6E987884-0994-4FBD-BBB2-EE2F695FA50B

P478

Q34101898-6ADB8F66-866B-4C01-B7EB-4659D4A1F5F4

P577

Q34101898-339BEECB-B0D0-4558-825D-61D9F5C06310

P698

Q34101898-0594F9DF-0BF1-47EF-8633-722975D0FDBE

P921

Q34101898-154D63CB-8399-46D3-B9B0-B4021F1AC6DC

Q34101898-2641210E-3CEC-45BF-8DE5-B6B09E9C7964

P356

WNL.0B013E3181D7D651

P1433

P1476

Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?

@en

P2093

B M J Uitdehaag

http://www.w3.org/2001/XMLSchema#string

F Barkhof

http://www.w3.org/2001/XMLSchema#string

H E Hulst

http://www.w3.org/2001/XMLSchema#string

J Drulovic

http://www.w3.org/2001/XMLSchema#string

K Matsuda

http://www.w3.org/2001/XMLSchema#string

MN166-001 Investigators

http://www.w3.org/2001/XMLSchema#string

R Landin

http://www.w3.org/2001/XMLSchema#string

P304

1033-1040

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181D7D651

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20200338

http://www.w3.org/2001/XMLSchema#string

P921

relapsing-remitting multiple sclerosis

multiple sclerosis